673 Shares in Intuitive Surgical, Inc. (NASDAQ:ISRG) Acquired by Kowal Investment Group LLC

Kowal Investment Group LLC bought a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 673 shares of the medical equipment provider’s stock, valued at approximately $299,000.

Other large investors have also recently added to or reduced their stakes in the company. Advisors Asset Management Inc. boosted its holdings in Intuitive Surgical by 18.1% during the first quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider’s stock worth $2,945,000 after buying an additional 1,129 shares in the last quarter. Public Employees Retirement System of Ohio boosted its stake in Intuitive Surgical by 5.4% in the 4th quarter. Public Employees Retirement System of Ohio now owns 191,283 shares of the medical equipment provider’s stock worth $64,531,000 after purchasing an additional 9,869 shares during the period. HCR Wealth Advisors boosted its stake in Intuitive Surgical by 26.3% in the 4th quarter. HCR Wealth Advisors now owns 1,042 shares of the medical equipment provider’s stock worth $352,000 after purchasing an additional 217 shares during the period. Artisan Partners Limited Partnership boosted its stake in Intuitive Surgical by 53.5% in the 4th quarter. Artisan Partners Limited Partnership now owns 63,851 shares of the medical equipment provider’s stock worth $21,541,000 after purchasing an additional 22,264 shares during the period. Finally, SWP Financial LLC acquired a new position in Intuitive Surgical in the 4th quarter worth approximately $255,000. 83.64% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Robert Desantis sold 1,413 shares of Intuitive Surgical stock in a transaction on Friday, July 26th. The shares were sold at an average price of $438.60, for a total value of $619,741.80. Following the transaction, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,414,931.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Amal M. Johnson sold 2,943 shares of Intuitive Surgical stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $443.30, for a total value of $1,304,631.90. Following the transaction, the director now owns 12,275 shares in the company, valued at approximately $5,441,507.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Robert Desantis sold 1,413 shares of Intuitive Surgical stock in a transaction on Friday, July 26th. The stock was sold at an average price of $438.60, for a total transaction of $619,741.80. Following the completion of the transaction, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,414,931.60. The disclosure for this sale can be found here. Insiders have sold 53,120 shares of company stock worth $25,528,753 in the last quarter. 0.90% of the stock is currently owned by company insiders.

Intuitive Surgical Trading Down 0.8 %

Intuitive Surgical stock opened at $486.20 on Friday. The company has a market capitalization of $172.46 billion, a P/E ratio of 87.76, a P/E/G ratio of 5.41 and a beta of 1.39. The firm’s fifty day simple moving average is $468.01 and its 200-day simple moving average is $425.12. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $496.18.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. The business had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. Intuitive Surgical’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.18 EPS. On average, equities research analysts predict that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Analysts Set New Price Targets

ISRG has been the subject of a number of recent analyst reports. Barclays raised their price objective on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a research note on Thursday, July 18th. Piper Sandler raised their price objective on shares of Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a research note on Friday, July 19th. Stifel Nicolaus raised their price objective on shares of Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a research note on Friday, July 19th. Truist Financial raised their price objective on shares of Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a research note on Tuesday, July 16th. Finally, The Goldman Sachs Group began coverage on shares of Intuitive Surgical in a research note on Thursday, May 30th. They set a “buy” rating and a $500.00 target price for the company. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $446.45.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.